Oral clindamycin causing acute cholestatic hepatitis.pdf (1.96 MB)
Oral clindamycin causing acute cholestatic hepatitis without ductopenia: a brief review of idiosyncratic drug-induced liver injury and a case report
journal contribution
posted on 2016-09-12, 00:00 authored by Harsha Moole, Zohair Ahmed, Nibha Saxena, Srinivas R. Puli, Sonu DhillonClindamycin is a lincosamide antibiotic active against most of the anaerobes, protozoans, and Gram-positive
bacteria, including community-acquired methicillin-resistant Staphylococcus aureus. Its use has increased
greatly in the recent past due to wide spectrum of activity and good bioavailability in oral form. Close to 20%
of the patients taking clindamycin experience diarrhea as the most common side effect. Hepatotoxicity is
a rare side effect. Systemic clindamycin therapy has been linked to two forms of hepatotoxicity: transient
serum aminotransferase elevation and an acute idiosyncratic liver injury that occurs 1 3 weeks after starting
therapy. This article is a case report of oral clindamycin induced acute symptomatic cholestatic hepatitis and a
brief review of the topic.
Funding
The Research Open Access Article Publishing (ROAAP) Fund of the University of Illinois at Chicago for financial support towards the open access publishing fee for this article.
History
Publisher Statement
This is a copy of an article published in the Journal of Community Hospital Internal Medicine Perspectives. © 2015 Harsha Moole et al.Publisher
Co-Action PublishingLanguage
- en_US
Issue date
2015-10-19Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC